CureVac (NASDAQ:CVAC – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $9.35 and last traded at $9.47, with a volume of 107 shares traded. The stock had previously closed at $9.57.
Analyst Ratings Changes
Separately, JMP Securities restated a "buy" rating and set a $37.00 target price on shares of CureVac in a research report on Thursday, June 9th.
Get
CureVac alerts:
CureVac Price Performance
The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.45. The firm has a 50 day moving average price of $12.02 and a 200-day moving average price of $15.09.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in CVAC. Capital Fund Management S.A. raised its stake in shares of CureVac by 131.9% during the 1st quarter. Capital Fund Management S.A. now owns 233,371 shares of the company's stock worth $4,576,000 after buying an additional 132,757 shares during the last quarter. Swiss National Bank acquired a new position in CureVac in the 2nd quarter valued at about $1,786,000. BlackRock Inc. raised its stake in CureVac by 6.2% in the 1st quarter. BlackRock Inc. now owns 1,915,548 shares of the company's stock valued at $37,564,000 after purchasing an additional 111,590 shares during the last quarter. Citigroup Inc. raised its stake in CureVac by 120.2% in the 1st quarter. Citigroup Inc. now owns 16,469 shares of the company's stock valued at $323,000 after purchasing an additional 98,177 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in CureVac by 156.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 158,520 shares of the company's stock valued at $2,157,000 after purchasing an additional 96,801 shares during the last quarter.
CureVac Company Profile
(Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
Featured Stories
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
